Clinical Research Directory
Browse clinical research sites, groups, and studies.
CoQ10 Effects on MDM Liver Fat Via FibroTouchI.
Sponsor: The 95th Hospital of Putian,Putian, Fujian, China
Summary
Mitochondrial diabetes mellitus (MDM) is a rare subtype of diabetes caused by mitochondrial dysfunction, often accompanied by hepatic steatosis. Coenzyme Q10 (CoQ10), a key electron carrier and antioxidant, may improve mitochondrial function and lipid metabolism. This prospective study aims to evaluate the effect of 12-week CoQ10 supplementation (300 mg/day) on liver fat content (assessed by FibroTouch CAP ) in MDM patients with m.3243A\>G mutation. An exploratory case-control design will compare baseline characteristics among MDM patients, type 1 diabetes patients, and healthy controls. This study is the first to explore the link between mitochondrial defects and hepatic fat accumulation specifically in MDM, and to test CoQ10 as a potential therapy, offering new insights for both MDM and MAFLD management.
Official title: The Effect of Coenzyme Q10 on Quantitative Changes in Hepatic Fat in Patients With Mitochondrial Diabetes
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-09
Completion Date
2027-12
Last Updated
2026-08-05
Healthy Volunteers
Yes
Conditions
Interventions
Coenzyme Q10 (drug)
This prospective study aims to evaluate the effect of 12 week CoQ10 supplementation (300 mg/day) on liver fat content (assessed by FibroTouch CAP) in MDM patients with m.3243A\>G mutation. An exploratory case control design will compare baseline characteristics among MDM patients, type 1 diabetes patients, and healthy controls.
Only undergo baseline assessments without intervention.
Only undergo baseline assessments without intervention.
Only undergo baseline assessments without intervention.
Only undergo baseline assessments without intervention.
Locations (1)
The 95th hospital of Putian
Putian, Fujian, China